These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8996607)

  • 1. A bacteriophage model system for studying topoisomerase inhibitors.
    Kreuzer KN
    Adv Pharmacol; 1994; 29B():171-86. PubMed ID: 8996607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors.
    Kreuzer KN
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):339-47. PubMed ID: 9748648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.
    Hong G; Kreuzer KN
    Mol Cell Biol; 2000 Jan; 20(2):594-603. PubMed ID: 10611238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of recombinational repair in sensitivity to an antitumour agent that inhibits bacteriophage T4 type II DNA topoisomerase.
    Neece SH; Carles-Kinch K; Tomso DJ; Kreuzer KN
    Mol Microbiol; 1996 Jun; 20(6):1145-54. PubMed ID: 8809767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases.
    Huff AC; Kreuzer KN
    J Biol Chem; 1990 Nov; 265(33):20496-505. PubMed ID: 2173709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repair of topoisomerase-mediated DNA damage in bacteriophage T4.
    Stohr BA; Kreuzer KN
    Genetics; 2001 May; 158(1):19-28. PubMed ID: 11333215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
    O'Reilly EK; Kreuzer KN
    Biochemistry; 2002 Jun; 41(25):7989-97. PubMed ID: 12069589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors.
    Freudenreich CH; Kreuzer KN
    EMBO J; 1993 May; 12(5):2085-97. PubMed ID: 8387918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.
    Freudenreich CH; Chang C; Kreuzer KN
    Cancer Res; 1998 Mar; 58(6):1260-7. PubMed ID: 9515814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes.
    Woodworth DL; Kreuzer KN
    Genetics; 1996 Jul; 143(3):1081-90. PubMed ID: 8807283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA nick processing by exonuclease and polymerase activities of bacteriophage T4 DNA polymerase accounts for acridine-induced mutation specificities in T4.
    Kaiser VL; Ripley LS
    Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2234-8. PubMed ID: 7892253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The specificity of topoisomerase-mediated DNA cleavage defines acridine-induced frameshift specificity within a hotspot in bacteriophage T4.
    Masurekar M; Kreuzer KN; Ripley LS
    Genetics; 1991 Mar; 127(3):453-62. PubMed ID: 1849858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-strand break repair and genetic recombination in topoisomerase and primase mutants of bacteriophage T4.
    Shcherbakov VP; Kudryashova E
    DNA Repair (Amst); 2014 Sep; 21():120-30. PubMed ID: 24811919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA.
    Huff AC; Ward RE; Kreuzer KN
    Mol Gen Genet; 1990 Mar; 221(1):27-32. PubMed ID: 2157956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion and duplication sequences induced in CHO cells by teniposide (VM-26), a topoisomerase II targeting drug, can be explained by the processing of DNA nicks produced by the drug-topoisomerase interaction.
    Ripley LS
    Mutat Res; 1994 Apr; 312(2):67-78. PubMed ID: 7510833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tight linkage between DNA replication and double-strand break repair in bacteriophage T4.
    George JW; Stohr BA; Tomso DJ; Kreuzer KN
    Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8290-7. PubMed ID: 11459966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hotspot sites for acridine-induced frameshift mutations in bacteriophage T4 correspond to sites of action of the T4 type II topoisomerase.
    Ripley LS; Dubins JS; deBoer JG; DeMarini DM; Bogerd AM; Kreuzer KN
    J Mol Biol; 1988 Apr; 200(4):665-80. PubMed ID: 2842508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombination-dependent DNA replication stimulated by double-strand breaks in bacteriophage T4.
    Kreuzer KN; Saunders M; Weislo LJ; Kreuzer HW
    J Bacteriol; 1995 Dec; 177(23):6844-53. PubMed ID: 7592477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriophage T4 DNA topoisomerase is the target of antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in T4-infected Escherichia coli.
    Huff AC; Leatherwood JK; Kreuzer KN
    Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1307-11. PubMed ID: 2537494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide inhibitors of DNA cleavage by tyrosine recombinases and topoisomerases.
    Klemm M; Cheng C; Cassell G; Shuman S; Segall AM
    J Mol Biol; 2000 Jun; 299(5):1203-16. PubMed ID: 10873446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.